Noxopharm Ltd. · ASX:NOX
Noxopharm — TechKnow Invest Roadshow 2019
42 slides from Noxopharm's conference presentation, Oct 22, 2019
Slide 1: Noxopharm and Nyrada Inc - TechKnow Invest Roadshow 2019 Presentations
For personal use only Date: 22 October 2019 Sydney, Australia ASX Limited 20 Bridge Street SYDNEY NSW 2000 Noxopharm and Nyrada Inc - TechKnow Invest Roadshow 2019 Presentations Sydney, 22 October 2019: Noxopharm (ASX: NOX) provides to the market the Noxopharm and Nyrada Inc corporate presentations
Slide 2: Forward Looking Statements
M: 0459 022 445 T: +61 2 9299 9690 E: Prue.Kelly@noxopharm.com E: David.Franks@automicgroup.com.au For personal use only Media Contact USA: Frank de Maria Purposeful Communications T: +1 347 647 0284 E: frank.demaria@purposefulcommunications.com Forward Looking Statements This announcement may conta
Slide 3: Noxopharm - October 2019
October 2019 For personal use only Dr Graham Kelly Founder and Executive Chairman DISCOVER DEVELOP DELIVER ASX: NOX © 2019 Noxopharm Ltd. All rights reserved.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in the For person
Slide 5: Key investor message
Key investor message For personal use only Noxopharm is seeking to bring to market a drug that restores the ability of the body’s immune system to fight and eliminate cancer Veyonda® A novel and potenMally transformaMve drug candidate in the fight against cancer © 2019 Noxopharm Ltd. All rights reserv
Slide 6: The problem
For personal use only The problem © 2019 Noxopharm Ltd. All rights reserved.
Slide 7: An unwelcome truth
An unwelcome truth For personal use only 1:2 men and 1:3 women will develop a life-threatening cancer 30% will die from that cancer within 5 years © 2019 Noxopharm Ltd. All rights reserved.
Slide 8: 10-year survival rates remain poor for many cancers
For personal use only APer After 45 45 years Years of of ‘the war Cytotoxic on cancer’….... Chemotherapy... 10-year survival rates remain poor for many cancers LiUle or • Pancreas no • Lung progress • Brain made in • Head and neck survival outcome • Oesophagus for • Stomach cancers • Cervix of: • Bl
Slide 9: Cancer represents avoidance of the body's immune system
CANCER represents avoidance of the body’s immune system For personal use only Emergence of cancer cell ‘Foreign’ cell detected → Immune cells arrive and immune cells acbvated eliminate cancer cell Tumour grows freely in Emergence of cancer cell Immune cells suppressed absence of immune function or r
Slide 10: The Solution
For personal use only The Solubon © 2019 Noxopharm Ltd. All rights reserved.
Slide 11: Immuno-oncology therapy
Immuno-oncology therapy …….. the transforming approach to cancer therapy For personal use only Aiming to restore the ability of the body’s immune system to recognize and kill cancer cells 2018 global sales = US$16 billion Projected to be > US$100 billion if response rates can be improved Current res
Slide 12: Converting cold tumours to hot tumours
Improving response rates to immuno-oncology drugs identified as needing to increase the immune activity inside tumours For personal use only Current global effort aiming to convert …… COLD tumours HOT tumours (No immune cells) (High number of immune cells) COLD HOT Majority of tumours believed to be
Slide 13: DARRT Treatment
For personal use only DARRT Treatment © 2019 Noxopharm Ltd. All rights reserved.
Slide 14: DARRT: Direct and Abscopal Response to Radiotherapy
DARRT Direct and Abscopal Response to Radiotherapy A novel way of converting tumours from COLD to HOT For personal use only Single tumour exposed RadiaMon damages Veyonda® boosts the to low-dose cancer cells → an immune response to radiotherapy inflammatory response the radiotherapy © 2019 Noxopharm
Slide 15: Palliative Radiotherapy
Palliative Radiotherapy - seeking to improve quality of life in late-stage cancer For personal use only • Low-dose • Designed to treat symptoms such as pain • Maximum 2 tumours irradiated • Not intended to stop disease progression Shrinkage of Irradiated tumor © 2019 Noxopharm Ltd. All rights reserv
Slide 16: DARRT: direct and abscopal responses
DARRT Direct and Abscopal Response to Radiotherapy For personal use only DARRT – Taking palliative radiotherapy and converting a modest immune response in a single irradiated tumour into a strong local immune response that spreads throughout the body DIRECT response ABSCOPAL response Shrinkage of Co
Slide 17: DARRT-1 clinical study
For personal use only DARRT-1 clinical study © 2019 Noxopharm Ltd. All rights reserved.
Slide 18: Prostate cancer and treatment options
Prostate cancer and treatment opMons Course of Disease and Treatment Journey for Stage I - IV Prostate Cancer For personal use only Surgery and/or Chemical Chemo- PalliaMve therapy local castrabon & Androgen therapy receptor radiotherapy therapy inhibitors Rising PSA levels in blood Hormone-sensibve
Slide 19: DARRT-1 study design and patients
DARRT DARRT-1 Direct and Abscopal Response to Radiotherapy For personal use only Ø 25 men with late-stage prostate cancer Ø Metastabc castrate-resistant prostate cancer (mCRPC) Ø No remaining standard treatment opbons Ø Progressive disease Ø Eligible for palliabve radiotherapy for symptomabc relief
Slide 20: DARRT-1 dosing schedule
DARRT DARRT-1 Direct and Abscopal Response to Radiotherapy For personal use only Day Day Up to 1 8 Day 15 Veyonda® Radiotherapy © 2019 Noxopharm Ltd. All rights reserved.
Slide 21: DARRT-1 results at 3 and 6 months
DARRT DARRT-1 Direct and Abscopal Response to Radiotherapy For personal use only 3-months 6-months No. pabents 22* 11** Mean star)ng PSA 623 ng/mL (1-3 normal range) PSA Response (>50% fall) 7 (33%) 2 Pain Response (>30% fall) 13 (60%) 6 (55%) RECIST No.pabents 22 10 Stable disease 13 (60%) 7 (70%)
Slide 22: DARRT-1 conclusions to date
DARRT Direct and Abscopal Response to Radiotherapy DARRT-1 For personal use only CONCLUSIONS TO DATE v The DARRT treatment has stopped disease progression in almost 3 out of 4 (73%) men with late-stage prostate cancer over 6 months v High (55%) incidence of pain reducbon over 6 months v Evidence of
Slide 23: DARRT-1 market opportunity
DARRT Direct and Abscopal Response to Radiotherapy DARRT-1 For personal use only MARKET OPPORTUNITY AUSTRALIA 2019 U.S.A. 2019 19,500 new cases 175,000 new cases 3,300 deaths (est) 31,600 deaths (est) © 2019 Noxopharm Ltd. All rights reserved.
Slide 24: DARRT Next steps
For personal use only DARRT Next steps © 2019 Noxopharm Ltd. All rights reserved.
Slide 25: DARRT-2 Clinical Study
DARRT Direct and Abscopal Response to Radiotherapy For personal use only DARRT-2 Clinical Study v To commence H2 2020 v Phase 2 adaptive v Control-arm study (palliative therapy) v Multiple sites, multi-national v Medical advisory boards established v Single course of radiotherapy/repeat cycles of Ve
Slide 26: Summary
For personal use only - Summary © 2019 Noxopharm Ltd. All rights reserved.
Slide 27: DARRT summary
DARRT Direct and Abscopal Response to Radiotherapy For personal use only v Current data showing DARRT delivering meaningful anti- cancer effects including pain relief over extended periods v Potentially transformative therapy for late-stage prostate cancer where no standard therapy exists currently
Slide 28: October 2019 - contact details
October 2019 For personal use only www.noxopharm.com graham.kelly@noxopharm.com DISCOVER DEVELOP DELIVER ASX: NOX © 2019 Noxopharm Ltd. All rights reserved.
Slide 29: Nyrada: Improving Lives, Offering Hope
For personal use only Improving Lives, Offering Hope James Bonnar Chief Executive Officer TechKnow INVEST ROADSHOW October 2019 1
Slide 30: Vision and Portfolio
Vision and Portfolio For personal use only To become a high-growth pharmaceutical company, specialising in drug Vision discovery and early-stage development in areas of substantial unmet clinical need, where few (if any) effective or well-tolerated therapies exist Cardiovascular Neurology Opportunit
Slide 31: The Cholesterol Problem
The Cholesterol Problem For personal use only 78 million Issue ADULTS IN THE US have high LDL cholesterol in the range considered high risk for heart disease and stroke 600k (1 in 4) DEATHS EACH YEAR in the US are attributed to cardiovascular disease US$317 billion CARDIOVASCULAR DISEASE COSTS IN TH
Slide 32: Current Standard of Care
Current Standard of Care For personal use only Standard Statin drugs block the liver’s ability to make LDL-cholesterol Treatment (Global sales of statin drugs in 2018 estimated to be US$19 billion) However… • Many patients are statin intolerant (12-20%) • Many patients do not achieve target ’healthy
Slide 33: PCSK9: Beyond Statin Therapy
PCSK9: Beyond Statin Therapy For personal use only Cholesterol and PCSK9 Current PCSK9 inhibitors PCSK9, a protein found in blood, plays a key role in regulating LDL cholesterol levels Statins reduce the production of LDL cholesterol To compensate, the liver produces more PCSK9 Statins increase PCSK
Slide 34: Our Cholesterol-Lowering Solution
Our Cholesterol-Lowering Solution For personal use only What’s Unique As far as we are aware, Nyrada is only 1 of 2 companies developing a small molecule PCSK9-inhibitor. Our aim is that our drug will pave the way for a single pill solution, for effective lowering of high LDL cholesterol. ✓ Benefit
Slide 35: Cholesterol-Lowering Drug: Market Overview (US)
Cholesterol-Lowering Drug: Market Overview (US) For personal use only Patient and Market Need Large potential market - There are approximately 18 million people in the U.S. with atherosclerotic cardiovascular disease (ASCVD) who live with elevated LDL levels despite taking maximally tolerated lipid-
Slide 36: Brain Injury Problem
Brain Injury Problem For personal use only Stroke Traumatic Brain Injury 0.8 million 2.8 million PEOPLE EACH YEAR PEOPLE EACH YEAR suffer a stroke in the US sustain a TBI in the US 140k (1 in 18) 50k (1 in 52) DEATHS EACH YEAR DEATHS EACH YEAR in the US are attributed to stroke in the US are attribu
Slide 37: Our Neuroprotection Solution
Our Neuroprotection Solution For personal use only Current Therapy Largely unmet clinical need • Clot-buster drugs (e.g. Alteplase) for treatment of acute ischemic stroke (approx. 87% of all stroke) • Therapeutics for traumatic brain injury limited to diuretics, anti-seizure, and coma-inducing drugs
Slide 38: Brain Injury Drug: Market Overview (US)
Brain Injury Drug: Market Overview (US) For personal use only Stroke Number of acute stroke emergency room visits per year in the US Approx. 656k Patients who present within nominal 12-hour therapeutic window (>75%) Approx. 490k Alteplase (tPA) sales approx. US$1.2 billion in 2017; average additiona
Slide 39: Program Status
Program Status For personal use only A staged research and development program to deliver preclinical and clinical validation subject to standard drug development risks • Proof-of-concept established for both the cholesterol-lowering and neuroprotection programs • Lead optimisation well-advanced − C
Slide 40: Board of Directors
Board of Directors For personal use only Nyrada operates under the direction of a board of international calibre, with track record in founding and realising the value of biotech companies Mr John John currently serves as Non-Executive Chairman of Trialogics, a clinical trial informatics business. J
Slide 41: Scientific Advisory Board
Scientific Advisory Board For personal use only Nyrada benefits from an international team of experts with deep experience in drug development to advise its board and management Scientia Professor Housley holds the Chair of Physiology and is director of the Translational Neuroscience Facility,School
Slide 42: James Bonnar, Chief Executive Officer
For personal use only James Bonnar Chief Executive Officer james.bonnar@nyrada.com www.nyrada.com 14